Brexpiprazole for schizophrenia and as adjunct for major depressive disorder

Por um escritor misterioso

Last updated 18 fevereiro 2025

Brexpiprazole for schizophrenia and as adjunct for major depressive disorder

Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data - ScienceDirect

Mechanism of action of brexpiprazole: comparison with aripiprazole, CNS Spectrums

A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder, Acta Neuropsychiatrica

FDA Approves New Schizophrenia Data for Rexulti - MPR

PDF) Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression

Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia - Clinical Trials Arena

What you need to know about Rexulti (Brexpiprazole)

Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies - ScienceDirect

Spotlight on brexpiprazole and its potential in the treatment of schiz

Aripiprazole, brexpiprazole, and cariprazine: Not all the same: Understanding the key differences among these agents can help inform treatment decisions - Document - Gale Academic OneFile

Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review

Recomendado para você